CYTKCytokinetics, Incorporated
Sign up free
Thesis

MYQORZO approved in US, EU, and UK with Phase 3 wins in two HCM subtypes; commercial ramp and BMS patent litigation are the tests

Updated 18d ago

Cytokinetics is a commercial-stage company with an approved targeted heart drug called MYQORZO that treats hypertrophic cardiomyopathy, a genetic condition that causes the heart muscle to thicken abnormally.

MYQORZO (aficamten), a cardiac myosin inhibitor for hypertrophic cardiomyopathy, holds approvals across the US, EU, and UK, with Q2 2026 net revenue of $25.3 million and over 1,500 patients dispensed. A positive ACACIA-HCM Phase 3 opens non-obstructive HCM as a second indication, with an sNDA planned for Q4 2026. The primary risk is the BMS/MyoKardia patent dispute, which could constrain commercial freedom if litigation resolves unfavorably, alongside competition from Edgewise Therapeutics' sevasemten in the same obstructive HCM population.

Status
Intact
Conviction

Current Thesis Drivers

  • MYQORZO approved US, EU, UK; revenue $25.3M Q2 2026
  • ACACIA-HCM met dual primaries in nHCM; NEJM published
  • $1.7B cash after $805M equity raise August 2026
  • BMS/MyoKardia patent suit filed; outcome unresolved

What could change the thesis?

  • Nov 14 PDUFA (MAPLE sNDA): approval expands label, rejection stalls oHCM monotherapy claim
  • nHCM sNDA filing Q4 2026: accepted validates second indication, rejected narrows market
  • Patent litigation outcome: CYTK wins preserves margins, BMS prevails threatens commercialization

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

5 programs · 13 catalysts

Stress Test